Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole Tartaglia, Marcel Bonn-Miller, and Randi Hagerman Cannabis and Cannabinoid Research, 2019, 4, 1 https://doi.org/10.1089/can.2018.0053 Abstract Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and [...]
Lire la suiteNeurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018 : Responders Versus Nonresponders Eef L. Theunissen, Nadia R.P.W. Hutten, Natasha L. Mason, Stefan W. Toennes, Kim P.C. Kuypers, and Johannes G. Ramaekers Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0047 Abstract Introduction : Synthetic cannabinoid mixtures have been easily accessible for years, leading to the belief that these products were natural and harmless, which contributed to their popularity. Nevertheless, there are many reports of users ending up in hospital due to severe side effects such as tachycardia, aggression, and psychosis. Controlled studies on the effects of synthetic cannabinoids on [...]
Lire la suiteRapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. Journal of Psychopharmacology, 2016, 30, 12, 1165-1180 DOI: 10.1177/0269881116675512 jop.sagepub.com Abstract Background : Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods : In this double-blind, placebo-controlled, crossover trial, 29 patients [...]
Lire la suitePsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. Journal of Psychopharmacology, 2016, 30, 12, 1181–1197. DOI: 10.1177/0269881116675513 jop.sagepub.com Abstract Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose [...]
Lire la suiteIncreased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression LYONS T., CARHART-HARRIS R.L. Journal of Psychopharmacology, 2018, 32, 7, 811-819. Doi : 10.1177/0269881117748902 journals.sagepub.com/home/jop Abstract Rationale : Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim : Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods : This open-label pilot study with a mixed-model design studied the effects of psilocybin on measures of nature relatedness and libertarian– authoritarian political perspective in patients with [...]
Lire la suiteEffects of psilocybin therapy on personnality structure ERRITZOE D., ROSEMAN L., NOUR M.M., MacLEAN K., KAELEN M., NUTT D.J., CARHART-HARRIS R.L. Acta Psychiatrica Scandinavica, 2018, 1-11. DOI : 10.1111/acps.12904 . Objective : To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (TRD). Method : Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin (10 and 25 mg, one week apart) in a supportive setting. Personality was assessed at baseline and at 3-month follow-up using the Revised NEO Personality Inventory (NEO-PI-R), the subjective psilocybin experience with Altered State of Consciousness (ASC) scale, and depressive symptoms with QIDS-SR16. Results : [...]
Lire la suiteQuality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, David J. Nutt, Robin L. Carhart-Harris Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom Frontiers in Pharmacology, 2018, 8, article 974. Doi : 10.3389/fphar.2017.00974 . Introduction : It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) [...]
Lire la suiteClinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder BOGENSCHUTZ M.P., PODREBARAC S.K., DUANE J.H., AMEGADZIE S.S., MALONE T.C., ROSS L.T., MENNENGA S.E. Frontiers in Pharmacology, 2018, 9, article 100. Doi : 10.3389/fphar.2018.00100 Abstract : After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process [...]
Lire la suiteCannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Progress in Neuropsychopharmacology & Biological Psychiatry, 2017. http://dx.doi.org/10.1016/j.pnpbp.2017.08.022 A B S T R A C T Methamphetamine (METH) is a widely abused and a severely addictive psychostimulant. Relapse is the main cause of concern when treating addiction. It could manifest after a long period of abstinence. Previous studies showed that there is a strong connection between sleep impairment and relapse. Also, it has been reported that cannabidiol might be a potential treatment for drug craving and relapse. [...]
Lire la suiteCannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats Gracie L. Hay, Sarah J. Baracz, Nicholas A. Everett, Jessica Roberts, Priscila A. Costa, Jonathon C. Arnold, Iain S. McGregor and Jennifer L. Cornish Journal of Psychopharmacology, 2018, 32, (12), 1369-1378. DOI : 10.1177/0269881118799954 , journals.sagepub.com/home/jop Abstract Background : Methamphetamine is an addictive stimulant that can cause many adverse physical, psychological and psychosocial effects. Preliminary evidence shows cannabidiol, a non-intoxicating constituent of the cannabis plant, may have efficacy in treating opioid and nicotine dependence. However, no study has yet examined whether cannabidiol treatment might impact on methamphetamine addiction. Aims : The current study [...]
Lire la suite